Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Heart Failure with CAD
NCT01877915Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2013
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and coronary artery disease (CAD) comparing Rivaroxaban with Placebo (2 arms). Primary endpoints: Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke up to 54 months and Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability up to 227 Weeks. Started Sep 2013; status: completed.
02
Drugs
rivaroxaban
03
Conditions
heart failure (HF)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01877915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01877915.